Mawson Infrastructure Group Inc. Announces Monthly Operational Update for November 2024
Total Monthly Digital Colocation Revenue grew 111% Y/Y in November 2024 Total Current Operating Hash Rate (EH) of about 4.98 […]
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market […]
Premier Health Reports 2024 Fourth Quarter Results
MONTRÉAL, Dec. 10, 2024 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech […]
Nutanix Announces Proposed $750 Million Convertible Senior Notes Offering
SAN JOSE, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) — Nutanix, Inc. (“Nutanix”) (Nasdaq: NTNX), a leader in hybrid multicloud computing, […]
Brookfield Corporation Announces Pricing of $700 Million Subordinated Notes Due 2055
BROOKFIELD, NEWS, Dec. 10, 2024 (GLOBE NEWSWIRE) — Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced the pricing of […]
New York Mortgage Trust Declares Fourth Quarter 2024 Common Stock Dividend of $0.20 Per Share, and Preferred Stock Dividends
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) — New York Mortgage Trust, Inc. (Nasdaq: NYMT) (the “Company”) announced today that […]
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the […]
Arogo Capital Acquisition Corp. Announces Binding Letter of Intent with Bangkok Tellink Co., Ltd, a Provider of Innovative Telecommunications and IoT Solutions, in Connection with a Proposed Business Combination Transaction
MIAMI, Fla. and BANGKOK, Dec. 10, 2024 (GLOBE NEWSWIRE) — Arogo Capital Acquisition Corp. (“Arogo Capital”) (OTC: AOGO) today announced […]
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
Phase 2b/3 trial of izokibep did not meet primary endpoint; secondary endpoints also did not achieve statistical significance Company continues […]
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company […]
